148 related articles for article (PubMed ID: 30738994)
1. PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism.
Altinoz MA; Ozpinar A
Int Immunopharmacol; 2019 Apr; 69():245-256. PubMed ID: 30738994
[TBL] [Abstract][Full Text] [Related]
2. Erucic acid, a component of Lorenzo's oil and PPAR-δ ligand modifies C6 glioma growth and toxicity of doxorubicin. Experimental data and a comprehensive literature analysis.
Altinoz MA; Bilir A; Elmaci İ
Chem Biol Interact; 2018 Oct; 294():107-117. PubMed ID: 30142312
[TBL] [Abstract][Full Text] [Related]
3. Erucic acid, a nutritional PPARδ-ligand may influence Huntington's disease pathogenesis.
Altinoz MA; Ozpinar A; Ozpinar A; Hacker E
Metab Brain Dis; 2020 Jan; 35(1):1-9. PubMed ID: 31625071
[TBL] [Abstract][Full Text] [Related]
4. PPARδ and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson's disease.
Altinoz MA; Elmaci İ; Hacimuftuoglu A; Ozpinar A; Hacker E; Ozpinar A
Mol Aspects Med; 2021 Apr; 78():100871. PubMed ID: 32703610
[TBL] [Abstract][Full Text] [Related]
5. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
6. Erucic Acid: A Possible Therapeutic Agent for Neurodegenerative Diseases.
Goyal A; Dubey N; Verma A; Agrawal A
Curr Mol Med; 2024; 24(4):419-427. PubMed ID: 37165502
[TBL] [Abstract][Full Text] [Related]
7. The X-linked adrenoleukodystrophy (X-ALD) and oxidative stress.
Al-Omar MA
J Herb Pharmacother; 2006; 6(3-4):125-34. PubMed ID: 17317654
[TBL] [Abstract][Full Text] [Related]
8. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).
Rasmussen M; Moser AB; Borel J; Khangoora S; Moser HW
Neurochem Res; 1994 Aug; 19(8):1073-82. PubMed ID: 7800117
[TBL] [Abstract][Full Text] [Related]
9. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
[TBL] [Abstract][Full Text] [Related]
10. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
[TBL] [Abstract][Full Text] [Related]
11. Effect of erucic acid on platelets in patients with adrenoleukodystrophy.
Kickler TS; Zinkham WH; Moser A; Shankroff J; Borel J; Moser H
Biochem Mol Med; 1996 Apr; 57(2):125-33. PubMed ID: 8733890
[TBL] [Abstract][Full Text] [Related]
12. Review of the potential pharmacological role of erucic acid: a monounsaturated omega-9 fatty acid.
Kazmi I; Afzal M; Al-Abbasi FA; AlGhamdi SA; Alghamdi AM; Alzarea SI; Almalki WH; AlGhamdi AS; Alkinani KB; Sayyed N
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3663-3674. PubMed ID: 38060041
[TBL] [Abstract][Full Text] [Related]
13. Adrenoleukodystrophy and the mitochondrial connection: clues for supplementing Lorenzo's oil.
Moraes CT
Brain; 2013 Aug; 136(Pt 8):2339-41. PubMed ID: 23842565
[No Abstract] [Full Text] [Related]
14. Lorenzo's oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid.
Sassa T; Wakashima T; Ohno Y; Kihara A
J Lipid Res; 2014 Mar; 55(3):524-30. PubMed ID: 24489110
[TBL] [Abstract][Full Text] [Related]
15. Adrenoleukodystrophy. The chain shortening of erucic acid (22:1(n-9)) and adrenic acid (22:4(n-6)) is deficient in neonatal adrenoleukodystrophy and normal in X-linked adrenoleukodistrophy skin fibroblasts.
Christensen E; Grønn M; Hagve TA; Kase BF; Christophersen BO
Biochim Biophys Acta; 1989 Mar; 1002(1):79-83. PubMed ID: 2538146
[TBL] [Abstract][Full Text] [Related]
16. Enhanced lymphocyte proliferation in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.
Pour RB; Stöckler-Ipsiroglu S; Hunneman DH; Gahr M; Korenke GC; Pabst W; Hanefeld F; Peters A
J Inherit Metab Dis; 2000 Mar; 23(2):113-9. PubMed ID: 10801052
[TBL] [Abstract][Full Text] [Related]
17. Normal natural killer cell activity in a patient with adrenoleukodystrophy treated with Lorenzo's oil.
Tanaka M; Koike R; Kuwabara T
Neurodegeneration; 1996 Jun; 5(2):192-4. PubMed ID: 8819141
[No Abstract] [Full Text] [Related]
18. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.
Poulos A; Gibson R; Sharp P; Beckman K; Grattan-Smith P
Ann Neurol; 1994 Nov; 36(5):741-6. PubMed ID: 7979219
[TBL] [Abstract][Full Text] [Related]
19. Severely depressed natural killer cell activity of patients with adrenoleukodystrophy under treatment with Lorenzo's oil.
Sedlmayr P; Plecko B; Paschke E; Zenz W; Ramschak H; Toplak H; Wascher TC; Wilders-Truschnig M; Stöckler S
J Inherit Metab Dis; 1995; 18(1):101-2. PubMed ID: 7623436
[No Abstract] [Full Text] [Related]
20. Effects of Lorenzo's Oil on peroxisomes in healthy mice.
De Craemer D; Van den Branden C; Fontaine M; Vamecq J
Prostaglandins Other Lipid Mediat; 1998 Mar; 55(4):237-44. PubMed ID: 9644114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
